Top 5 Low Price Companies To Watch In Right Now

The following video is from Thursday's MarketFoolery podcast, in which host Chris Hill and analysts Andy Cross and Matt Koppenheffer discuss the top business and investing stories of the day.

Costco (NASDAQ: COST  ) reported a 19% increase in third-quarter profit and shares of the retailer hit an all-time high in the wake of the news. What's behind Costco's success? Will the retailer continue to be a big hit on Wall Street? In this installment of MarketFoolery, our analysts discuss the future of Costco.

Costco's low prices haven't just benefited customers -- shareholders have walloped the market, returning 11,000% over the past two decades. However, with prices near all-time highs, is the ride over for Costco investors? To answer that and more, The Motley Fool's compiled a premium research report with in-depth analysis on Costco.�Simply click here now to gain instant access to this valuable investor's resource.

Top 5 Low Price Companies To Watch In Right Now: Reed Resources Ltd(RDR.AX)

Reed Resources Ltd engages in the mining and exploration of mineral properties in Western Australia. The company explores for steel, lithium, gold, nickel, vanadium, and iron ore deposits. Its principal projects include, the Meekatharra gold project located in the Murchison region; the Mount Marion lithium project located to the south of Kalgoorlie in the Goldfields region; the Comet Vale gold project located to the north of Kalgoorlie; the Mount Finnerty project, an iron ore and nickel project situated to the east of Koolyanobbing; and the Barrambie Vanadium project located in the mid west region of Western Australia. The company also owns interests in the Bell Rock Range nickel project located in the western part of the Proterozoic Musgrave Block in central Australia. Reed Resources Ltd is based in West Perth, Australia.

Top 5 Low Price Companies To Watch In Right Now: MakeMusic Inc.(MMUS)

MakeMusic, Inc. develops and markets music education technology solutions that transform how music is composed, taught, learned, and performed. It offers SmartMusic, an interactive music teaching and learning solution for band, orchestra, and vocal students to use at schools and homes; SmartMusic Gradebook, a Web-based grade book for teachers to post assignments to students, receive completed assignments from students, assess student achievement, and manage student records; and SmartMusic Inbox, a free application for Android and Apple platforms. The company also provides Finale family of music notation products for use with Macintosh and Windows PC operating systems that enable a musician to enter musical data into a computer using the computer keyboard, a musical instrument digital interface (MIDI)-equipped electronic music keyboard, or other MIDI-equipped instruments, as well as to display the data on a computer screen as a musical score. Its SmartMusic software solutio ns serve public and private school music administrators, instrumental music educators, and their students primarily in the United States and Canada; and Finale family of notation products serve composers, arrangers, publishers, and music teachers worldwide. The company markets its SmartMusic software solutions directly through its Website, smartmusic.com; and Finale family of notation products through channel-specific distributors and retailers in musical instrument, educational, and consumer electronic channels, as well as directly through its Website. MakeMusic, Inc. was founded in 1990 and is based in Eden Prairie, Minnesota.

Top 10 Regional Bank Stocks To Invest In 2014: WaterFurnace Renewable Energy Inc (WFIFF.PK)

WaterFurnace Renewable Energy, Inc. specializes in the design, manufacture and distribution of geothermal and water-source systems. It�� the United States subsidiary companies are WaterFurnace International, Inc. (WaterFurnace) and LoopMaster International, Inc. (LoopMaster). In December 2010, it incorporated two Australian subsidiaries: WaterFurnace International Asia Pacific Pty. Ltd. (WaterFurnace Asia Pacific) and Hyper WFI Pty. Ltd. (Hyper WFI). WaterFurnace designs, manufactures and distributes geothermal water source heating and cooling systems for residential, commercial and institutional buildings. LoopMaster installs geothermal loops for residential applications, does commercial conductivity testing and provides design and installation assistance. Hyper WFI designs, develops and builds devices that limit the inrush current, which electric motors draw upon start up. On January 21, 2011, the Company acquired inventory and fixed assets from Binary Engineering Pty. Ltd.

Top 5 Low Price Companies To Watch In Right Now: Telik Inc (TELK)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�� drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

Clinical Product Development

TELINTRA is the Company�� lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tolerated. In June 2011, the Company initiated a Phase II clinical ! trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. '

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transfusions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolerability of the combinations was similar to that expected of each! drug alo! ne.

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

Preclinical Drug Product Development

The Company has a small molecule compound, TLK60404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multiple, standard preclinical models of cancer. TLK60596, a potent VG! FR kinase! inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

Top 5 Low Price Companies To Watch In Right Now: Phylogica Ltd(PYC.AX)

Phylogica Limited, a biotechnology company, engages in the discovery and development of peptide based therapeutic candidates in Australia. The company provides drug discovery services to the pharmaceutical industry utilizing its Phylomer libraries and screening methodologies. Its proprietary Phylomer libraries contain various peptides that represent a source of biologically active drug leads for a range of intracellular and extracellular disease targets; and Phylomer peptides are bioactive fragments of naturally occurring proteins that are encoded in the genomes of evolutionary diverse microbes. Phylomer peptides include protein interactions that promote various diseases, such as infectious diseases, cancer, autoimmunity, and heart diseases. The company has approximately 16 patent families comprising multiple granted/allowed patents in the United States and Australia, which cover methods of making the Phylomer libraries, methods of screening them and composition-of-matter claims for Phylomer libraries, and individual Phylomer peptides discovered for therapeutic and diagnostic applications. Phylogica Limited is headquartered in Perth, Australia.